Literature DB >> 17878639

Health-related quality of life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal study.

Hiromi Tomioka1, Kazufumi Imanaka, Kimio Hashimoto, Hironobu Iwasaki.   

Abstract

OBJECT: To validate the cross-sectional and longitudinal use of the Medical Outcome Study Short Form 36 (SF-36) for measuring health-related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF).
METHODS: Patients were administered the SF-36 and concomitantly underwent laboratory and physiologic tests and high-resolution computed tomography (HRCT). Forty-six patients participated in the initial cross-sectional study, and 32 patients who were available more than one year later again underwent these studies under the same conditions.
RESULTS: Patients with IPF had significantly lower scores across all 8 domains of the SF-36 when compared with the general population. Significant decline of HRQL was observed in 2 physical domains. There were significant differences in within-subject changes in a few domains according to worsening of the physiologic parameters. Vital capacity as percent of predicted was significantly correlated with the results of 6 subscales and its changes were significantly correlated with those of 4 subscales. The 6-min-walk distance was correlated significantly with 3 subscales and its changes were significantly correlated with those of 4 subscales. Changes in the HRCT ground-glass score were significantly correlated with those of 3 subscales. No significant correlations between changes in 3 domains and those of any clinical parameters were observed.
CONCLUSION: Patients with IPF had significantly impaired HRQL in both physical and psychological functions. This disease clearly decreased the physical aspects of HRQL over time. HRQL instruments should be incorporated into routine evaluations of IPF patients, since they measure dimensions not fully estimated by clinical assessment.

Entities:  

Mesh:

Year:  2007        PMID: 17878639     DOI: 10.2169/internalmedicine.46.6218

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  30 in total

1.  The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.

Authors:  Jeffrey J Swigris; Frederick S Wamboldt; Juergen Behr; Roland M du Bois; Talmadge E King; Ganesh Raghu; Kevin K Brown
Journal:  Thorax       Date:  2009-12-08       Impact factor: 9.139

2.  Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis.

Authors:  Geetika Verma; Theodore Marras; Nouri Chowdhury; Lianne Singer
Journal:  Can Respir J       Date:  2011 Sep-Oct       Impact factor: 2.409

3.  Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners.

Authors:  Kathleen Oare Lindell; Ellen Olshansky; Mi-Kyung Song; Thomas G Zullo; Kevin F Gibson; Naftali Kaminski; Leslie A Hoffman
Journal:  Heart Lung       Date:  2009-11-20       Impact factor: 2.210

4.  Identifying Mechanisms of Homeostatic Signaling in Fibroblast Differentiation.

Authors:  Hayley C Warsinske; Shanna L Ashley; Jennifer J Linderman; Bethany B Moore; Denise E Kirschner
Journal:  Bull Math Biol       Date:  2015-09-18       Impact factor: 1.758

Review 5.  Idiopathic pulmonary fibrosis: early detection and referral.

Authors:  Justin M Oldham; Imre Noth
Journal:  Respir Med       Date:  2014-04-04       Impact factor: 3.415

6.  The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.

Authors:  Jeffrey J Swigris; Kevin K Brown; Juergen Behr; Roland M du Bois; Talmadge E King; Ganesh Raghu; Frederick S Wamboldt
Journal:  Respir Med       Date:  2009-10-07       Impact factor: 3.415

Review 7.  Psychiatric aspects of chronic lung disease.

Authors:  Abhishek Jain; Sermsak Lolak
Journal:  Curr Psychiatry Rep       Date:  2009-06       Impact factor: 5.285

8.  Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.

Authors:  Jared T Hagaman; Brent W Kinder; Mark H Eckman
Journal:  Lung       Date:  2010-04       Impact factor: 2.584

9.  Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1).

Authors:  G Raghu; T E King; J Behr; K K Brown; R M du Bois; I Leconte; S Roux; J Swigris
Journal:  Eur Respir J       Date:  2009-08-13       Impact factor: 16.671

10.  Gender influences Health-Related Quality of Life in IPF.

Authors:  MeiLan K Han; Jeffrey Swigris; Lyrica Liu; Brian Bartholmai; Susan Murray; Nicholas Giardino; Bruce Thompson; Margaret Frederick; Daner Li; Marvin Schwarz; Andrew Limper; Kevin Flaherty; Fernando J Martinez
Journal:  Respir Med       Date:  2009-12-24       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.